Recce Pharmaceuticals announces positive trial results

Recce Pharmaceuticals (ASX:RCE) has announced promising interim results from its Phase II clinical trial of RECCE® 327 Gel. The topical therapy is being tested for its effectiveness against acute bacterial skin and skin structure infections, including diabetic foot infections. An independent review confirmed that the gel is safe and well-tolerated, with all patients showing improvement or achieving a complete cure.

Recce Pharmaceuticals' Phase II trial summary and outlook

The Phase II trial of RECCE® 327 Gel by Recce Pharmaceuticals is progressing well, with no serious adverse events reported, supporting the continuation of the study. The trial is expected to complete within the year, aiming to address unmet medical needs in serious bacterial infection treatments. Recce Pharmaceuticals is focused on developing synthetic anti-infectives to combat antibiotic-resistant pathogens, with a pipeline that includes treatments for bacterial and viral infections. The company is positioned to capitalize on the growing market for ABSSSI treatments, projected to reach $26 billion USD by 2032.

Insights from Recce Pharmaceuticals on trial outcomes

The independent review panel's unanimous agreement on the safety and efficacy of R327G is a significant milestone for Recce Pharmaceuticals. The results are highly encouraging, with some patients showing full recovery as early as seven days. This supports our continued research and development efforts in providing effective treatments for bacterial infections.